Trial register facet
Trial records in atherosclerotic cardiovascular disease and cardiovascular risk reduction
71 records bearing on atherosclerotic cardiovascular disease and cardiovascular risk reduction.
Showing 0 records on this page
Records
71 documents · page 1 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SOUL | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,650 | 2025 | Moderate |
| SURPASS-CVOT | Tirzepatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 13,299 | 2025 | Moderate |
| SURPASS-CVOT-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-RENAL-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SURPASS-CVOT-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-PKprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-DDIprogramme record | Semaglutide, oral | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SURPASS-CVOT-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SOUL-HEPATIC-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SELECT | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 17,604 | 2023 | High |
| SELECT-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2023 | Very low |
| SURPASS-4 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 2,002 | 2021 | High |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| SURPASS-4-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| SURPASS-4-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| AMPLITUDE-O-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| SURPASS-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| AMPLITUDE-O-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| SURPASS-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| PIONEER-6 | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,183 | 2019 | High |
| REWIND | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,901 | 2019 | High |
| PIONEER-6-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
page 1 of 3